Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report.
Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report.
复制标题
DOI：
10.1007/s10067-022-06126-x
复制
发表时间：
2022-05
影响因子：
3.4
通讯作者：
Aggarwal R
中科院分区：
文献类型：
--
作者：
Lemoine C;Padilla C;Krampe N;Doerfler S;Morgenlander A;Thiel B;Aggarwal R
辉瑞-BioNTech COVID-19疫苗已获得美国食品和药物管理局的授权，因为它对SARS-CoV-2病毒的有效性达到95%。虽然最初的疫苗试验显示出有利的副作用，但人们担心会激活异常免疫反应，引发自身免疫。这是一名68岁女性的病例报告，她没有自身免疫性疾病史，在接受辉瑞-BioNTech COVID-19疫苗7天后来到我们的急诊室。她最初的症状提示风湿性多肌痛，她对类固醇几乎完全反应。有趣的是，考虑到炎症性关节炎、ANA阳性和dsDNA阳性的发展，她后来符合系统性狼疮的分类标准。她在接种疫苗后2天开始出现症状的时间关系可能表明辉瑞-BioNTech COVID-19与系统性红斑狼疮的发生之间可能存在关联。
The Pfizer-BioNTech COVID-19 vaccine has been authorized by the U.S. Food and Drug Administration as it demonstrated 95% effectiveness against the SARS-CoV-2 virus. Although the initial vaccine trials showed a favorable side effect profile, there have been concerns regarding activation of aberrant immune responses, triggering autoimmunity. This is a case report of a 68-year-old woman without history of autoimmune conditions, who presented to our emergency department 7 days after receiving the Pfizer-BioNTech COVID-19 vaccine. Her initial symptoms were suggestive of polymyalgia rheumatica, and she had nearly complete response to steroids. Interestingly, she later met criteria for classified systemic lupus erythematous given the development of inflammatory arthritis, positive ANA, and positive dsDNA. The temporal relationship of her symptoms that started 2 days after vaccine administration could suggest a possible association between the Pfizer-BioNTech COVID-19 and the development of systemic lupus erythematous.
登录
查看更多内容
影响因子：
2.8
作者：
Lazaro, Deana
通讯作者：
Lazaro, Deana
影响因子：
5
作者：
Gadotti AC;de Castro Deus M;Telles JP;Wind R;Goes M;Garcia Charello Ossoski R;de Padua AM;de Noronha L;Moreno-Amaral A;Baena CP;Tuon FF
通讯作者：
Tuon FF
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
10.4
作者：
Radwi, Mansoor;Farsi, Sara
通讯作者：
Farsi, Sara
DOI：
10.1016/j.bbih.2021.100217
发表时间：
2021-05
期刊：
Brain, behavior, & immunity - health
影响因子：
--
作者：
Repajic M;Lai XL;Xu P;Liu A
通讯作者：
Liu A